Biotech News
Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
investor.lineagecell.com2026-05-06 15:27 EST
Positive RG6501 (OpRegen ® ) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for Sensorineural Hearing Loss Initiated Manufacturing Scale Project in Type 1 Diabetes Cell Therapy